

# Codon-specific *KRAS* mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

Received: 11 January 2022

Accepted: 26 January 2023

Published online: 2 March 2023

 Check for updates


A list of authors and their affiliations appears at the end of the paper

Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome analysis of 37 patients with metastatic colorectal cancer (mCRC) treated with the chemotherapy trifluridine/tipiracil (FTD/TPI), we identified *KRAS* codon G12 (*KRAS*<sup>G12</sup>) mutations as a potential biomarker of resistance. Next, we collected real-world data of 960 patients with mCRC receiving FTD/TPI and validated that *KRAS*<sup>G12</sup> mutations were significantly associated with poor survival, also in analyses restricted to the *RAS/RAF* mutant subgroup. We next analyzed the data of the global, double-blind, placebo-controlled, phase 3 RECURSE trial ( $n = 800$  patients) and found that *KRAS*<sup>G12</sup> mutations ( $n = 279$ ) were predictive biomarkers for reduced overall survival (OS) benefit of FTD/TPI versus placebo (unadjusted interaction  $P = 0.0031$ , adjusted interaction  $P = 0.015$ ). For patients with *KRAS*<sup>G12</sup> mutations in the RECURSE trial, OS was not prolonged with FTD/TPI versus placebo ( $n = 279$ ; hazard ratio (HR) = 0.97; 95% confidence interval (CI) = 0.73–1.20;  $P = 0.85$ ). In contrast, patients with *KRAS*<sup>G13</sup> mutant tumors showed significantly improved OS with FTD/TPI versus placebo ( $n = 60$ ; HR = 0.29; 95% CI = 0.15–0.55;  $P < 0.001$ ). In isogenic cell lines and patient-derived organoids, *KRAS*<sup>G12</sup> mutations were associated with increased resistance to FTD-based genotoxicity. In conclusion, these data show that *KRAS*<sup>G12</sup> mutations are biomarkers for reduced OS benefit of FTD/TPI treatment, with potential implications for approximately 28% of patients with mCRC under consideration for treatment with FTD/TPI. Furthermore, our data suggest that genomics-based precision medicine may be possible for a subset of chemotherapies.

Systemic anticancer therapy based on the chemotherapeutic agents 5-fluorouracil (5-FU)/capecitabine, oxaliplatin and irinotecan in combination with epidermal growth factor receptor (EGFR) or vascular endothelial growth factor inhibitors are the cornerstone of the treatment of metastatic colorectal cancer (mCRC)<sup>1</sup>. More recently, the chemotherapeutic drug trifluridine/tipiracil (FTD/TPI), a combination

of trifluridine (FTD), a nucleoside analog, and tipiracil (TPI), a thymidine phosphorylase inhibitor, has been approved for patients with advanced, heavily pretreated mCRC<sup>2–4</sup>. Although durable responses to FTD/TPI have been observed in some patients with mCRC, the median overall survival (OS) benefit in the general population with mCRC is modest (1.8 months), highlighting the unmet need for patient selection<sup>1,3,5–9</sup>.

✉ e-mail: [e.voest@nki.nl](mailto:e.voest@nki.nl); [n.valeri@imperial.ac.uk](mailto:n.valeri@imperial.ac.uk)



**Fig. 1 | Discovery of  $KRAS^{G12}$  mutation status as potential biomarker of outcome of FTD/TPI treatment in mCRC. a**, Dot plot showing the associations of candidate genomic biomarkers to OS on FTD/TPI treatment in the discovery cohort ( $n = 37$  patients). The exact log-rank test statistic ( $\theta$ ) for the death of patients with the candidate biomarker versus those without is plotted against the Benjamini–Hochberg-corrected FDR. The red line indicates the 5% FDR

significance threshold. **b**, A Kaplan–Meier curve of OS in the discovery cohort for patients without (black) or with (red) a  $KRAS^{G12}$  mutation. Censoring events are indicated by vertical bars on the corresponding curve. The dotted lines indicate the median OS. The table underneath the plot denotes the numbers at risk. The exact log-rank test-based two-sided  $P$  is shown. FDR, false discovery rate; OS, overall survival.

Precision medicine is widely used to select patients for targeted therapies and immunotherapies for mCRC according to the presence or absence of genomic biomarkers. As such, the detection of  $KRAS$  hotspot mutations is a critical step in the diagnostic workup of mCRC as  $RAS/RAF$  mutations predict clinical resistance to EGFR-targeting antibodies<sup>10–12</sup>. Such  $KRAS$  mutations are found in 44% of patients with mCRC; these most frequently occur at codon G12 ( $KRAS^{G12}$ ; 28% of patients) or codon G13 ( $KRAS^{G13}$ ; 8% of patients) (Extended Data Fig. 1 and Supplementary Table 1)<sup>13</sup>. Although  $KRAS^{G12}$  and  $KRAS^{G13}$  mutations are regarded as a single entity in clinical practice guidelines, they have different biochemical properties<sup>14,15</sup> and display tissue- and treatment-specific mutational patterns<sup>16</sup>.

In this study, given the lack of genomic biomarkers and the limited clinical benefit of FTD/TPI in unselected patients with mCRC, we harnessed the power of whole-genome somatic profiles coupled with patient outcomes to identify biomarkers of response and resistance to FTD/TPI. Key findings were then validated in a real-world cohort of FTD/TPI-treated patients with mCRC ( $n = 960$ ) and in the double-blind, placebo-controlled, phase 3 RECURSE trial ( $n = 800$ ; study overview shown in Extended Data Fig. 2).

## Results

### $KRAS^{G12}$ mutations as potential biomarkers for FTD/TPI treatment

We first performed whole-genome analysis of a real-world discovery cohort that consisted of 37 patients with mCRC from the publicly available Hartwig Medical Foundation database<sup>17</sup>, who received FTD/TPI treatment in a standard-of-care setting in 13 hospitals across the Netherlands (Hartwig Medical Foundation (HMF) cohort; Supplementary Table 2). In accordance with late-stage disease, the median OS was relatively short, that is, 6.1 months (95% confidence interval (CI) = 4.2–8.3). Ten genomic drivers occurred in at least five patients and were tested as candidate biomarkers for OS (Supplementary Table 3 and Methods). After correction for multiple-hypothesis testing,  $KRAS^{G12}$  status was most significantly associated with reduced OS (exact log-rank test-based two-sided  $P = 0.0016$ ; Benjamini–Hochberg false discovery rate (FDR) = 0.016; threshold for significance,  $FDR < 0.05$ ; Fig. 1a,b and Supplementary Table 4). Besides 20 patients with  $KRAS^{G12}$  mutations, the cohort also included four patients with  $KRAS$  mutations at other codons. Consideration of all  $KRAS$  mutations combined in

a codon-agnostic manner diluted the observed effect (Fig. 1a,b and Supplementary Table 4). Similar results were obtained when time on FTD/TPI treatment was used as the end point (Extended Data Fig. 3 and Supplementary Table 5). Based on these hypothesis-generating results, we wondered if  $KRAS^{G12}$  mutation status could be a determinant of FTD/TPI treatment outcome in mCRC.

### $KRAS$ mutations and real-world survival on FTD/TPI treatment

We next collected real-world data of 960 patients with mCRC who were treated with FTD/TPI in 36 centers across Italy and the UK (Supplementary Tables 6 and 7). Based on routine diagnostics (largely performed at diagnosis), the cohort contained 385 patients with  $RAS/RAF$  wild-type (WT) tumors, 343 patients with  $KRAS^{G12}$  mutations, 86 patients with  $KRAS^{G13}$  mutations, 53 patients with  $KRAS$  mutations at codons other than G12 or G13 ( $KRAS^{other}$ ), 32 patients with  $BRAF$  mutations and 61 patients with  $NRAS$  mutations. In the full population, patients with  $KRAS^{G12}$  mutations had more frequent right-sided disease and more recent diagnoses of metastatic disease (Table 1). Importantly, these factors were well balanced when patients with  $KRAS^{G12}$  mutations were compared to patients with other  $RAS/RAF$  mutations, or specifically to those with hotspot mutations affecting the directly adjacent codon  $KRAS^{G13}$ , whereas this latter subgroup had relatively good performance status (Table 1).

In the real-world validation cohort, codon-specific  $RAS/RAF$  mutations were significantly associated with clear differences in OS on treatment with FTD/TPI (log-rank  $P < 0.001$ ; Fig. 2a). Again,  $KRAS^{G12}$  mutations were significantly associated with poor OS, with a similar effect in the population as a whole (unadjusted hazard ratio (HR) for death = 1.31; 95% CI = 1.11–1.55;  $P = 0.0017$ ; adjusted HR for death = 1.24; 95% CI = 1.04–1.47,  $P = 0.016$ ; Fig. 2b, left panel), as in the  $RAS/RAF$  mutant subpopulation (unadjusted HR for death = 1.30; 95% CI, 1.04–1.61,  $P = 0.019$ ; adjusted HR for death, 1.28; 95% CI 1.03–1.60,  $P = 0.027$ ; Fig. 2b, middle panel). Notably, the OS of patients with  $KRAS^{G12}$  mutations was also poor as compared with patients with  $KRAS^{G13}$  mutations (unadjusted HR for death = 1.79; 95% CI = 1.29–2.48;  $P < 0.001$ ; adjusted HR for death = 1.61; 95% CI = 1.15–2.26,  $P = 0.0061$ ; Fig. 2b, right panel). Similar results were obtained when the analysis was based on progression-free survival (PFS) (Extended Data Fig. 4). Patients with  $KRAS^{G12}$  mutations did not show significantly shorter OS than patients in any of the other, smaller  $RAS/RAF$  mutant subgroups (those with

**Table 1 | Baseline characteristics of patients in the real-world validation cohort, stratified according to codon-specific RAS/RAF mutation status**

Characteristic	Overall (n=960)	KRAS <sup>G12</sup> (n=343)	KRAS <sup>G13</sup> (n=86)	KRAS <sup>Other</sup> (n=53)	BRAF <sup>mut</sup> (n=32)	NRAS <sup>mut</sup> (n=61)	RAS/RAF <sup>WT</sup> (n=385) <sup>b</sup>	Overall (n=960)G12 versus no G12	RAS/RAF <sup>mut</sup> (n=575)G12 versus no G12	KRAS <sup>exon_2_mut</sup> (n=429) <sup>a</sup> G12 versus G13
<b>Age</b>										
Median (IQR)	64 (56–71)	65 (57–72)	63 (56–72)	64 (60–69)	66 (57–72)	65 (56–73)	64 (55–71)	P=0.44	P=0.92	P=0.70
<65	484 (50)	168 (49)	46 (53)	28 (53)	16 (50)	28 (46)	198 (51)	P=0.54	P=0.78	P=0.47
≥65	476 (50)	175 (51)	40 (47)	25 (47)	16 (50)	33 (54)	187 (49)			
<b>Sex</b>										
Female	390 (41)	140 (41)	45 (52)	22 (42)	5 (16)	23 (38)	155 (40)	P=0.95	P=1.0	P=0.067
Male	570 (59)	203 (59)	41 (48)	31 (58)	27 (84)	38 (62)	230 (60)			
<b>Country</b>										
Italy	827 (86)	289 (84)	78 (91)	47 (89)	28 (88)	54 (89)	331 (86)	P=0.21	P=0.11	P=0.17
UK	133 (14)	54 (16)	8 (9)	6 (11)	4 (12)	7 (11)	54 (14)			
<b>ECOG performance score</b>										
0–1	820 (85)	292 (85)	83 (97)	42 (79)	23 (72)	53 (87)	327 (85)	P=0.85	P=0.28	<b>P=0.0031</b>
≥2	140 (15)	51 (15)	3 (3)	11 (21)	9 (28)	8 (13)	58 (15)			
<b>Primary site of disease</b>										
Colon	696 (71)	262 (76)	62 (72)	37 (70)	24 (75)	42 (69)	269 (70)	P=0.050	P=0.24	P=0.40
Rectum	264 (28)	81 (24)	24 (28)	16 (30)	8 (25)	19 (31)	116 (30)			
<b>Sidedness</b>										
Left	661 (69)	205 (60)	53 (62)	34 (64)	18 (56)	43 (70)	308 (80)	<b>P&lt;0.001</b>	P=0.40	P=0.81
Right <sup>c</sup>	299 (31)	138 (40)	33 (38)	19 (36)	14 (44)	18 (30)	77 (20)			
<b>Time from diagnosis of metastases</b>										
<18 months	275 (28)	117 (34)	27 (31)	19 (36)	16 (50)	20 (33)	76 (20)	<b>P=0.0073</b>	P=0.77	P=0.70
≥18 months	678 (71)	225 (66)	59 (69)	34 (64)	15 (47)	40 (66)	305 (79)			
Unknown	7 (1)	1 (0)	0 (0)	0 (0)	1 (3)	1 (2)	4 (1)			
<b>Previous surgery</b>										
No	229 (24)	84 (24)	15 (17)	11 (21)	12 (38)	19 (31)	88 (23)	P=0.75	P=0.75	P=0.20
Yes	729 (76)	259 (76)	70 (81)	42 (79)	20 (62)	42 (69)	296 (77)			
Unknown	2 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	1 (0)			
<b>Peritoneal disease at the start of FTD/TPI treatment</b>										
No	604 (63)	203 (59)	56 (65)	32 (60)	17 (53)	38 (62)	258 (67)	P=0.070	P=0.51	P=0.33
Yes	355 (37)	140 (41)	30 (35)	21 (40)	15 (47)	22 (36)	127 (33)			
Unknown	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)			
<b>MMR status</b>										
Proficient	563 (59)	197 (56)	59 (69)	34 (64)	20 (62)	38 (62)	215 (56)	P=0.55	P=1.0	P=0.69
Deficient	28 (3)	8 (2)	1 (1)	4 (8)	3 (9)	0 (0)	12 (3)			
Unknown	369 (38)	138 (40)	26 (30)	15 (28)	9 (28)	23 (38)	158 (41)			


<sup>a</sup>KRAS<sup>exon\_2\_mut</sup>: patients with KRAS exon 2 mutations (KRAS<sup>G12</sup> and KRAS<sup>G13</sup>). <sup>b</sup>RAS/RAF<sup>WT</sup>: patients without KRAS, NRAS or BRAF mutations. <sup>c</sup>Right-sided disease, including five patients with multiple primary tumors at both sides. Two-sided P values (bold for P<0.05) were used for comparisons between subgroups as indicated by the headers, using a Fisher's exact test for categorical variables (excluding unknowns) and a Wilcoxon rank-sum test for continuous age. IQR, interquartile range.

KRAS<sup>other</sup>, BRAF or NRAS mutations; statistics not shown). Together, this independent validation confirmed that patients with KRAS<sup>G12</sup> mutant mCRC have relatively poor OS on treatment with FTD/TPI. Furthermore, the clear OS difference between patients with KRAS<sup>G12</sup> and KRAS<sup>G13</sup> mutations underwrites the rationale for considering KRAS mutations in a codon-specific manner.

#### KRAS mutations and survival in the RECURSE trial

To further strengthen our findings and investigate if our observations were based on prognostic or predictive effects, we analyzed the

data of a large, independent, placebo-controlled clinical cohort, the RECURSE trial<sup>3</sup>. Briefly, this international, randomized, double-blind, placebo-controlled, phase 3 study assigned 800 heavily pretreated patients with mCRC to receive either FTD/TPI or placebo in a 2:1 ratio. Based on routine diagnostics (largely performed at diagnosis), approximately half of the patients (n = 393) were KRAS<sup>WT</sup>, whereas the other half (n = 407) were KRAS mutant. In this study, KRAS mutation status (mutated yes/no) was not significantly associated with reduced OS or PFS benefit of FTD/TPI versus placebo; however, codon-specific analyses were not performed<sup>3,4</sup>.



**Fig. 2 | Associations of *RAS/RAF* mutations with the OS of 960 patients with mCRC receiving FTD/TPI treatment in a real-world setting. **a**, Kaplan–Meier curve of OS in the full population, stratified according to *RAS/RAF* mutations, as indicated by the colors (see the table underneath the plot for the color coding used for each *RAS/RAF* mutation category). Censoring events are indicated by vertical bars on the corresponding curve. The dotted lines and corresponding annotation indicate the subgroup-specific median OS. The table underneath the plot denotes the numbers at risk. The two-sided log-rank test-based  $P$  value is shown. **b**, Kaplan–Meier curves of OS in the full population (left), *RAS/RAF***

mutant population (middle) and *KRAS*<sup>exon 2,mut</sup> population (right), stratified according to the presence (red) or absence (black) of a *KRAS*<sup>G12</sup> mutation. Censoring events are indicated by vertical bars on the corresponding curve. The dotted lines indicate the subgroup-specific median OS. The table underneath each plot denotes the numbers at risk. Two-sided Wald test-based  $P$  values are shown. <sup>a</sup>Unadjusted by univariate Cox regression. <sup>b</sup>Adjusted by stratified, multivariate Cox regression, adjusted for eight baseline characteristics (Methods). Note that all Cox regression models passed the proportional-hazards assumption. OS, overall survival.

Codon-specific mutational status was available for 367 out of 407 (90%) patients with *KRAS*-mutated tumors in the RECURSE trial. Of these, 279 (76%) had *KRAS*<sup>G12</sup> mutations, 60 (16%) had *KRAS*<sup>G13</sup> mutations, 21 (5.7%) were reported to have *KRAS*<sup>G12/G13</sup> double mutations (largely due to the use of analytical methods that could not discriminate between the two codons) and 7 (1.9%) had other mutations. (The true percentage of patients with other mutations was probably higher because their assessment was only broadly implemented later<sup>11</sup>.)

Throughout our analyses, we considered patients with *KRAS*<sup>G12/G13</sup> double mutations as a distinct subgroup.

The prespecified baseline characteristics of the RECURSE trial were well balanced between the FTD/TPI and placebo arms in *KRAS*<sup>G12</sup> mutant, *KRAS*<sup>G13</sup> mutant and *KRAS*<sup>WT</sup> subgroups (Table 2), with some exceptions; patients whose tumors harbored a *KRAS* mutation generally had more recent diagnoses of metastatic disease, were less heavily pretreated and were more frequently refractory to fluoropyrimidine

**Table 2 | Baseline characteristics of patients in the RECURSE trial intention-to-treat population, stratified according to codon-specific *KRAS* mutation status**

Characteristic	<i>KRAS</i> <sup>G12</sup>			<i>KRAS</i> <sup>G13</sup>			<i>KRAS</i> <sup>WT</sup>			G12 versus G13	G12 versus WT	G13 versus WT
	FTD/TPI (n=185)	P	Placebo (n=94)	FTD/TPI (n=40)	P	Placebo (n=20)	FTD/TPI (n=262)	P	Placebo (n=131)			
<b>Age</b>												
<65	114 (62)	P=0.44	53 (56)	23 (57)	P=0.17	7 (35)	138 (53)	P=0.52	74 (56)	P=0.19	P=0.13	P=0.58
≥65	71 (38)		41 (44)	17 (43)		13 (65)	124 (47)		57 (44)			
<b>Sex</b>												
Female	78 (42)	P=0.80	38 (40)	19 (48)	P=0.42	7 (35)	93 (35)	P=0.66	50 (38)	P=0.86	P=0.20	P=0.32
Male	107 (58)		56 (60)	21 (53)		13 (65)	169 (65)		81 (62)			
<b>Region</b>												
Japan	63 (34)	P=0.19	40 (43)	9 (23)	P=1.00	4 (20)	94 (36)	P=0.31	40 (31)	<b>P=0.025</b>	P=0.46	P=0.075
USA, Europe and Australia	122 (66)		54 (57)	31 (78)		16 (80)	168 (64)		91 (69)			
<b>ECOG</b>												
0	110 (59)	P=0.61	59 (63)	23 (57)	P=1.00	11 (55)	151 (58)	<b>P=0.042</b>	61 (47)	P=0.66	P=0.097	P=0.78
1	75 (41)		35 (37)	17 (43)		9 (45)	111 (42)		70 (53)			
<b>Primary site of disease</b>												
Colon	124 (67)	P=0.19	55 (59)	23 (57)	P=0.15	16 (80)	157 (60)	P=0.83	77 (59)	P=1.0	P=0.23	P=0.48
Rectum	61 (33)		39 (41)	17 (43)		4 (20)	105 (40)		54 (41)			
<b>Time from diagnosis of metastases</b>												
<18 months	51 (28)	P=0.89	25 (27)	13 (33)	P=0.58	8 (40)	39 (15)	P=0.88	18 (14)	P=0.27	<b>P&lt;0.001</b>	<b>P&lt;0.001</b>
≥18 months	134 (72)		69 (73)	27 (68)		12 (60)	223 (85)		113 (86)			
<b>No. of previous regimens</b>												
2	52 (28)	P=0.95	26 (28)	13 (33)	P=0.76	8 (40)	25 (10)	P=0.37	8 (6)	P=0.34	<b>P&lt;0.001</b>	<b>P&lt;0.001</b>
3	50 (27)		24 (26)	7 (18)		4 (20)	51 (19)		22 (17)			
≥4	83 (45)		44 (47)	20 (50)		8 (40)	186 (71)		101 (77)			
<b>Refractory to fluoropyrimidine as part of last previous regimen</b>												
Yes	135 (73)	P=0.56	72 (77)	30 (75)	P=0.54	13 (65)	117 (45)	P=0.19	49 (37)	P=0.75	<b>P&lt;0.001</b>	<b>P&lt;0.001</b>
No	50 (27)		22 (23)	10 (25)		7 (35)	145 (55)		82 (63)			
<b>Prior use of regorafenib</b>												
Yes	31 (17)	P=0.60	13 (14)	5 (13)	P=1.00	3 (15)	41 (16)	P=0.12	29 (22)	P=0.84	P=0.53	P=0.47
No	154 (83)		81 (86)	35 (88)		17 (85)	221 (84)		102 (78)			
<b>No. of metastatic sites</b>												
1–2	109 (59)	P=0.30	62 (66)	22 (55)	P=0.79	10 (50)	166 (63)	P=0.064	70 (53)	P=0.31	P=0.75	P=0.33
≥3	76 (41)		32 (34)	18 (45)		10 (50)	96 (37)		61 (47)			


Two-sided *P* values (bold for *P*<0.05) are for comparisons between codon-specific *KRAS* mutation status-based subgroups, using Fisher's exact test for categorical variables with two classes and chi-squared test for categorical variables with more than two classes. ECOG, Eastern Cooperative Oncology Group.

as part of the last previous regimen (Table 2). Importantly, all these factors were balanced between the *KRAS*<sup>G12</sup> and *KRAS*<sup>G13</sup> mutant populations. Between these two groups, the only significant difference was that patients with *KRAS*<sup>G13</sup> mutations originated less often from Japan (Table 2).

To understand the prognostic effects of codon-specific *KRAS* mutations in the trial population, we first analyzed OS in the placebo arm (Extended Data Fig. 5). This showed that patients with the *KRAS*<sup>G12</sup> and *KRAS*<sup>WT</sup> mutants had similar OS. Interestingly, placebo-treated patients with *KRAS*<sup>G13</sup> mutations (the other main *KRAS* mutant subgroup in the study) had a remarkably shorter OS than those with *KRAS*<sup>G12</sup> mutations (median OS *KRAS*<sup>G13</sup> mutants: 2.9 months, 95% CI = 2.1–6.1 months versus median OS *KRAS*<sup>G12</sup> mutants: 5.8 months, 95% CI = 4.7–7.3; HR = 2.20; 95% CI = 1.25–3.86; *P* = 0.0060; Extended Data Fig. 5), which held after adjustment for the ten baseline characteristics

(HR = 2.46; 95% CI = 1.33–4.57; *P* = 0.0043; Extended Data Fig. 5). In the placebo arm, patients with *KRAS*<sup>G13</sup> mutant tumors also had shorter OS than those with *KRAS*<sup>WT</sup> tumors, which was statistically significant in unadjusted analysis (HR = 1.95; 95% CI = 1.13–3.36; *P* = 0.017; Extended Data Fig. 5), but did not attain statistical significance in the adjusted analysis (HR = 1.79; 95% CI = 0.96–3.32; *P* = 0.065; Extended Data Fig. 5). Taken together, these analyses indicate that *KRAS*<sup>G12</sup> mutations are not associated with poor prognosis in late-stage mCRC.

We then studied if *KRAS*<sup>G12</sup> mutations were predictive biomarkers for reduced OS benefit of FTD/TPI in the RECURSE trial. In the *KRAS*<sup>G12</sup> mutant population (*n* = 279 patients), OS was not prolonged with FTD/TPI versus placebo (HR = 0.96; 95% CI = 0.71–1.29; *P* = 0.78; Fig. 3a, upper left). Within the full study population (*n* = 800 patients), *KRAS*<sup>G12</sup> mutations were significantly associated with a reduced OS benefit of FTD/TPI versus placebo (unadjusted interaction *P* = 0.0031;



**Fig. 3 | KRAS mutations and OS benefit of FTD/TPI versus placebo in the RECURSE trial. a**, Kaplan–Meier curves of OS with FTD/TPI (red) or placebo (black) for patients with KRAS<sup>G12</sup> mutations (upper left panel), without KRAS<sup>G12</sup> mutations (upper right panel), with KRAS<sup>G13</sup> mutations (lower left panel) and without KRAS mutations (lower right panel). Censoring events are indicated by vertical bars on the corresponding curve. The dotted lines indicate the median OS. The table underneath each plot denotes the numbers at risk. Two-sided Wald test-based *P* values are shown. **b**, Forest plot of HRs for death and 95% CIs for patients treated with FTD/TPI versus placebo, subgrouped according to codon-specific KRAS mutation status. Two-sided Wald test-based *P* values

for interaction (as calculated using Cox regression) indicate if the OS benefit of FTD/TPI treatment versus placebo was significantly different between subgroups, for which pairwise comparisons are indicated by the square brackets. <sup>a</sup>Unadjusted: stratified for two stratification factors of the trial (time from diagnosis of metastases (<18 versus ≥18 months) and region (Japan versus USA, Europe and Australia)). <sup>b</sup>Adjusted: adjusted by the two stratification factors used in unadjusted analysis plus eight additional baseline characteristics (Methods). Note that all Cox regression models passed the proportional-hazards assumption. NE, not estimated; OS, overall survival.

adjusted interaction  $P = 0.015$ ; Fig. 3b; full regression model fits shown in Supplementary Table 8). In analyses restricted to the subgroup with *KRAS* mutations ( $n = 407$  patients), *KRAS*<sup>G12</sup> mutations were also significantly associated with reduced OS benefit of FTD/TPI versus placebo (unadjusted interaction  $P = 0.0091$ ; adjusted interaction  $P = 0.0037$ ; full regression model fits shown in Supplementary Table 8). Further stratification of patients with *KRAS*<sup>G12</sup> mutations according to different amino acid changes did not provide evidence of OS benefit with FTD/TPI versus placebo in any subgroup (Extended Data Fig. 6). Taken together, these data demonstrate that FTD/TPI treatment did not lead to a clinically relevant prolongation of OS in patients with mCRC with *KRAS*<sup>G12</sup> mutations in the RECURSE trial.

When patients whose tumors harbored a *KRAS*<sup>G12</sup> mutation were excluded from the analysis, FTD/TPI resulted in a pronounced OS benefit over placebo ( $n = 521$ ; HR = 0.55; 95% CI = 0.45–0.69;  $P < 0.001$ ; Fig. 3a, upper right), with a median OS benefit of 2.7 months in this subgroup (versus 1.8 months in the full population, as reported by Mayer et al.<sup>3</sup>).

Next, we analyzed the treatment effect of FTD/TPI in patients with *KRAS*<sup>G13</sup> mutant tumors. In sharp contrast to the *KRAS*<sup>G12</sup> mutant population, patients with the *KRAS*<sup>G13</sup> mutation showed a clear OS benefit in the FTD/TPI arm versus the placebo arm (HR = 0.34; 95% CI = 0.17–0.67;  $P = 0.0018$ ; Fig. 3a, lower left). This remained significant in the adjusted analysis (HR = 0.21; 95% CI = 0.090–0.48;  $P < 0.001$ ; Fig. 3b). The median OS was three times longer in the FTD/TPI arm versus the placebo arm (8.7 versus 2.9 months; Fig. 3). The OS benefit of FTD/TPI treatment was significantly more pronounced in patients with *KRAS*<sup>G13</sup>-mutated mCRC versus those with *KRAS*<sup>G12</sup>-mutated disease (unadjusted interaction  $P = 0.0026$ ; adjusted interaction  $P = 0.0023$ ; Fig. 3b; the full regression model fits are shown in Supplementary Table 8). Thus, *KRAS*<sup>G13</sup> mutations marked patients with clear OS benefit from FTD/TPI treatment.

We then assessed PFS in *KRAS* codon-specific subgroups of the RECURSE trial. A minimal PFS benefit of FTD/TPI versus placebo was observed in all three subgroups (median PFS benefit 0.1, 0.3 and 0.3 months for patients with *KRAS*<sup>G12</sup>, *KRAS*<sup>G13</sup> and *KRAS*<sup>WT</sup> mutations, respectively), which did not significantly differ among these subpopulations (interactions nonsignificant for all pairwise comparisons; Extended Data Fig. 7).

### *KRAS*<sup>G12</sup> mutations and FTD/TPI resistance in vitro

Finally, we aimed to replicate these findings in vitro using isogenic cell lines and mCRC patient-derived organoids (PDOs) ( $n = 7$ ; Supplementary Table 9). *KRAS*<sup>G12</sup> mutation knock in significantly reduced responsiveness to FTD (the cytotoxic component of FTD/TPI) in two colorectal cancer cell line models, SW48 and Colo320 (two-sided Wilcoxon rank-sum-based  $P = 0.029$  for both models; Fig. 4a–d). The parental models are *KRAS*<sup>WT</sup> and do not harbor other frequent mCRC oncogenic drivers like mutations in *NRAS*, *BRAF*, *PTEN* or *PIK3CA*. Similar results were obtained with PDOs, with *KRAS*<sup>G12</sup>-mutated lines consistently showing reduced FTD responsiveness (two-sided Wilcoxon rank-sum-based  $P = 0.034$ ; Fig. 4e,f). Notably, the presence of a *KRAS*<sup>G12</sup> mutation was associated with suppression of FTD-induced DNA damage (as measured by γH2AX) in both isogenic cell lines and PDOs (Fig. 4g,h). We next tested in vitro sensitivity to 5-FU because this chemotherapeutic is closely related to FTD/TPI but exerts its main effect through damaging RNA rather than DNA. In all models, *KRAS*<sup>G12</sup> mutations did not significantly reduce in vitro sensitivity to 5-FU (Fig. 4i–l). Of note, the higher sensitivity to FTD in *KRAS*<sup>WT</sup> models could not be explained by higher baseline proliferation rates, as the (untreated) *KRAS*<sup>WT</sup> PDOs demonstrated lower proliferation rates than (untreated) *KRAS*<sup>G12</sup> PDOs (Extended Data Fig. 8). Taken together, these results show that *KRAS*<sup>G12</sup> mutation-based resistance to FTD can be modeled in vitro and is characterized by limited FTD-induced DNA damage.

## Discussion


Using two independent real-world datasets from three different countries and an independent validation cohort based on the global, double-blind, placebo-controlled, phase 3 RECURSE trial, we demonstrate that codon-specific *KRAS* mutations predict OS benefit for patients treated with the chemotherapeutic agent FTD/TPI in late-stage mCRC. Specifically, *KRAS*<sup>G12</sup> mutations identify patients who experience no clinically relevant<sup>18</sup> survival benefit from FTD/TPI, while the remaining population—including *KRAS*<sup>G13</sup>-mutated patients—benefits substantially. The RECURSE trial showed only a modest OS benefit of FTD/TPI versus placebo in the general, unselected population with mCRC. In this context, our results offer a framework to (re)assess the risk–benefit profile of FTD/TPI according to codon-specific *KRAS* mutations. Given that *KRAS* testing is routinely performed in the molecular workup of all patients with CRC to guide treatment with EGFR-targeting agents<sup>11</sup>, our findings can be readily adopted in the clinic.

In line with previous clinical and preclinical evidence<sup>14–16</sup>, our data demonstrate that *KRAS*<sup>G12</sup> and *KRAS*<sup>G13</sup> mutated mCRC are different clinical entities. The former disease is characterized by better prognosis but shows no clinically relevant OS benefit of FTD/TPI treatment (predictive effect), whereas the latter disease behaves aggressively when treated with placebo but can be more effectively managed with FTD/TPI treatment. These data caution against lumping together *KRAS* mutations at different codons in biomarker analyses and clinical trial designs because different biological and biochemical properties may be associated with different clinical outcomes.

The primary objective of the RECURSE trial was to detect differences in OS between FTD/TPI and placebo, the gold standard outcome measure for regulatory approval studies for new treatments for metastatic cancer<sup>19,20</sup>. One of the reasons for this is that marginal improvements in PFS may not translate into an OS benefit<sup>21</sup> as we observe in the subpopulation of the RECURSE trial with *KRAS*<sup>G12</sup> mutant tumors. The main caveat of OS is that lines of treatment administered after progression on the study drug might bias the conclusions. Notably, information on 5-FU-based rechallenges was not collected in the RECURSE trial but are unlikely to underlie the reduced OS benefit of FTD/TPI in the population with *KRAS*<sup>G12</sup> mutations. The reason is that this would require that placebo-treated patients with *KRAS*<sup>G12</sup> mutations received considerably more treatments after progression in the study than FTD/TPI-treated patients with *KRAS*<sup>G12</sup> mutations. Nevertheless, even in this unlikely scenario the conclusion would still be that, in terms of OS, the treatment with FTD/TPI has not been a useful intervention because it did not provide a relevant OS benefit over treatment with placebo.

Analysis of the real-world validation cohort showed that mismatch repair (MMR) deficiency was rare (Table 1) and was not associated with *KRAS*<sup>G12</sup> status nor with OS of patients treated with FTD/TPI (data not shown). Furthermore, tumor sidedness was well balanced among all *RAS/RAF*-based subgroups of the real-world cohort and adjustment for this covariate in multivariate models did not affect our conclusions. In addition, pretreatment variables, such as the number of previous regimens, refractoriness to fluoropyrimidine or previous use of regorafenib were not responsible for our results. Namely, our RECURSE trial-based analyses showed that these (1) were well balanced between the populations with *KRAS*<sup>G12</sup> and *KRAS*<sup>G13</sup> mutant tumors, (2) were not associated with OS benefit of FTD/TPI versus placebo and (3) did not alter our conclusions when incorporated into multivariate models.

While all *RAS/RAF*-based subgroups were molecularly well defined in our real-world datasets, this classification was not as complete in the RECURSE trial. Indeed, *KRAS* hotspot mutations outside codons G12 and G13 were only tested in a small fraction of the RECURSE trial population and data on *NRAS* and *BRAF* mutations were (largely) missing. Given the results of our real-world analyses, patients with *KRAS* mutations outside of codons G12 and G13 or *BRAF* mutations may more closely resemble patients with *KRAS*<sup>G12</sup> mutations; inclusions



**Fig. 4 | *KRAS*<sup>G12</sup> mutations and in vitro resistance to FTD in isogenic cell lines and PDOs of mCRC.** **a**, Colony formation assay for *KRAS*<sup>WT</sup> and *KRAS*<sup>G12V</sup> SW48 colorectal cancer cell lines after 2 weeks' exposure to a concentration range of FTD in vitro. **b**, As in **a**, but for *KRAS*<sup>WT</sup> and *KRAS*<sup>G12D</sup> isogenic Colo320 CRC cell lines. **c**, Dose–response curves of *KRAS*<sup>WT</sup> (black) and *KRAS*<sup>G12</sup> (red) isogenic SW48 (dots) or Colo320 (diamonds) CRC cell lines exposed to a concentration range of FTD in vitro. The dots and error bars represent the mean and s.d. among four biological replicates at the tested concentrations, respectively. **d**, Half-maximal inhibitory concentrations ( $IC_{50}$ ;  $\log_2$ ) for FTD of *KRAS*<sup>WT</sup> and *KRAS*<sup>G12</sup> isogenic SW48 or Colo320 CRC cell lines, as indicated on the x axis. Data are plotted for four biological replicates. The box center lines, box ranges, whiskers and dots indicate the medians, quartiles, 1.5 times the IQR and data points of individual experiments (biological replicates;  $n = 4$  for each line), respectively. The two-sided Wilcoxon rank-sum test-based  $P$  value is shown. **e**, Dose–response curves of mCRC PDOs harboring WT *KRAS* (black;  $n = 3$ ) or different *KRAS*<sup>G12</sup> mutations

(red;  $n = 4$ ) exposed to FTD in vitro. The dots and error bars represent the mean and s.d. at the tested concentrations, respectively. **f**,  $IC_{50}$  ( $\log_2$ ) for FTD of *KRAS*<sup>WT</sup> (black;  $n = 3$ ) and *KRAS*<sup>G12</sup> (red;  $n = 4$ ) mCRC PDOs. The box center lines, box ranges, whiskers and dots indicate the medians, quartiles, 1.5 times the IQR and data points of individual organoid lines (see legend), respectively. The two-sided Wilcoxon rank-sum test-based  $P$  value is shown. **g**, Representative western blot of the DNA damage marker  $\gamma$ H2AX on treatment of *KRAS*<sup>WT</sup> (black) and *KRAS*<sup>G12</sup> (red) SW48 (left) and Colo320 (right) cells with FTD at increasing concentrations. Hsp90 was used as a loading control. Data were confirmed in three and two biological replicates for SW48 and Colo320, respectively. **h**, As in **g**, but for mCRC PDOs harboring *KRAS*<sup>WT</sup> (black, left) or different *KRAS*<sup>G12</sup> mutations (red, right). The left and right panels were exposed together (Source Data 1). Data were confirmed in three biological replicates. **i**, As in **c** but for 5-FU. **j**, As in **d** but for 5-FU. **k**, As in **e** but for 5-FU. **l**, As in **f** but for 5-FU.

of these cases in the *KRAS*<sup>WT</sup> group might have underestimated the survival benefit conferred by FTD/TPI in the 'real' *KRAS*<sup>WT</sup> population. A further observation with potential clinical implications relates to the fact that virtually all *KRAS*<sup>WT</sup> patients in our cohorts were pretreated with anti-EGFR therapeutics, while their *RAS* (and *RAF*) status was determined before any therapy. Given that *RAS* mutations can emerge as drivers of acquired resistance in this scenario<sup>22</sup>, some patients might have been misclassified. Although the above considerations are important to keep in mind when interpreting the results, our conclusions hold

regardless because such misclassifications may only have diluted the differences between the analyzed subgroups.

A potential limitation of our study is that this investigator-initiated reanalysis of the RECURSE trial was not predefined in the original trial protocol. However, based on our findings, this reanalysis was hypothesis-driven and prespecified in a formal data request before access to the RECURSE trial data was granted.

Several clinico-pathological and molecular biomarkers of benefit to FTD/TPI have been tested but none has reached clinical application<sup>23</sup>.



Our results show that *KRAS* mutational analysis, a standard-of-care test already implemented worldwide, can identify patients with *KRAS*<sup>G12</sup> mutant mCRC who are unlikely to benefit from FTD/TPI treatment, avoiding unnecessary toxicities to patients and rationalizing the use of resources for healthcare systems. Thus, we report the first proof of genomics-based precision medicine for a chemotherapy in mCRC, which has the potential to substantially improve patient selection for FTD/TPI treatment.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-023-02240-8>.

## References

1. Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann. Oncol.* **27**, 1386–1422 (2016).
2. Marcus, L. et al. FDA approval summary: TAS-102. *Clin. Cancer Res.* **23**, 2924–2927 (2017).
3. Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N. Engl. J. Med.* **372**, 1909–1919 (2015).
4. Van Cutsem, E. et al. The subgroups of the phase III RECURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. *Eur. J. Cancer* **90**, 63–72 (2018).
5. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N. Engl. J. Med.* **350**, 2335–2342 (2004).
6. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N. Engl. J. Med.* **360**, 1408–1417 (2009).
7. Venook, A. P. et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with *KRAS* wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. *JAMA* **317**, 2392–2401 (2017).
8. Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. *Lancet Oncol.* **16**, 1306–1315 (2015).
9. Jonker, D. J. et al. Cetuximab for the treatment of colorectal cancer. *N. Engl. J. Med.* **357**, 2040–2048 (2007).
10. Allegra, C. J. et al. American Society of Clinical Oncology provisional clinical opinion: testing for *KRAS* gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. *J. Clin. Oncol.* **27**, 2091–2096 (2009).
11. Allegra, C. J. et al. Extended *RAS* gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. *J. Clin. Oncol.* **34**, 179–185 (2016).
12. Karapetis, C. S. et al. *K-ras* mutations and benefit from cetuximab in advanced colorectal cancer. *N. Engl. J. Med.* **359**, 1757–1765 (2008).
13. Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat. Med.* **23**, 703–713 (2017).
14. Lu, S. et al. Ras conformational ensembles, allostery, and signaling. *Chem. Rev.* **116**, 6607–6665 (2016).
15. Ostrem, J. M. & Shokat, K. M. Direct small-molecule inhibitors of *KRAS*: from structural insights to mechanism-based design. *Nat. Rev. Drug Discov.* **15**, 771–785 (2016).
16. Li, S., Balmain, A. & Counter, C. M. A model for *RAS* mutation patterns in cancers: finding the sweet spot. *Nat. Rev. Cancer* **18**, 767–777 (2018).
17. Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. *Nature* **575**, 210–216 (2019).
18. Ellis, L. M. et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. *J. Clin. Oncol.* **32**, 1277–1280 (2014).
19. Schnipper, L. E. et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. *J. Clin. Oncol.* **33**, 2563–2577 (2015).
20. Cherny, N. I. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). *Ann. Oncol.* **28**, 2901–2905 (2017).
21. Johnson, K. R. et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. *Lancet Oncol.* **7**, 741–746 (2006).
22. Misale, S. et al. Emergence of *KRAS* mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature* **486**, 532–536 (2012).
23. Voutsadakis, I. A. Biomarkers of trifluridine-tipiracil efficacy. *J. Clin. Med.* **10**, 5568 (2021).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

Joris van de Haar<sup>1,2,3</sup>, Xuhui Ma<sup>1,3,4,6</sup>, Salo N. Ooft<sup>1,3,4,6</sup>, Pim W. van der Helm<sup>1,3,4,6</sup>, Louisa R. Hoes<sup>1,3</sup>, Sara Mainardi<sup>2,3</sup>, David J. Pinato<sup>4,5,6</sup>, Kristi Sun<sup>6</sup>, Lisa Salvatore<sup>7,8</sup>, Giampaolo Tortora<sup>7,8</sup>, Ina Valeria Zurlo<sup>9</sup>, Silvana Leo<sup>9</sup>, Riccardo Giampieri<sup>10</sup>, Rossana Berardi<sup>10</sup>, Fabio Gelsomino<sup>11</sup>, Valeria Merz<sup>12</sup>, Federica Mazzuca<sup>13</sup>, Lorenzo Antonuzzo<sup>14,15</sup>, Gerardo Rosati<sup>16</sup>, Chara Stavraka<sup>17,18</sup>, Paul Ross<sup>18</sup>, Maria Grazia Rodriquenz<sup>19</sup>, Michele Pavarana<sup>20</sup>, Carlo Messina<sup>21</sup>, Timothy Iveson<sup>22</sup>, Federica Zoratto<sup>23</sup>, Anne Thomas<sup>24</sup>, Elisabetta Fenocchio<sup>25</sup>, Margherita Ratti<sup>26</sup>, Ilaria Depetris<sup>27</sup>, Massimiliano Cergnul<sup>28</sup>, Cristina Morelli<sup>29</sup>, Michela Libertini<sup>30</sup>, Alessandro Parisi<sup>10,31</sup>, Michele De Tursi<sup>32</sup>,

**Nicoletta Zanaletti<sup>33</sup>, Ornella Garrone<sup>34</sup>, Janet Graham<sup>35</sup>, Raffaella Longarini<sup>36</sup>, Stefania Maria Gobba<sup>37</sup>, Angelica Petrillo<sup>38</sup>, Emiliano Tamburini<sup>39</sup>, Nicla La Verde<sup>40</sup>, Fausto Petrelli<sup>41</sup>, Vincenzo Ricci<sup>42</sup>, Lodewyk F. A. Wessels<sup>2,3,43</sup>, Michele Ghidini<sup>34</sup>, Alessio Cortellini<sup>4,44</sup>, Emile E. Voest<sup>1,3,47</sup> ✉ & Nicola Valeri<sup>4,45,47</sup> ✉**

<sup>1</sup>Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. <sup>2</sup>Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands. <sup>3</sup>Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. <sup>4</sup>Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. <sup>5</sup>Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. <sup>6</sup>Imperial College Healthcare NHS Trust, London, UK. <sup>7</sup>Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Roma, Italy. <sup>8</sup>Oncologia Medica, Università Cattolica del Sacro Cuore, Roma, Italy. <sup>9</sup>Medical Oncology, 'Vito Fazzi' Hospital, Lecce, Italy. <sup>10</sup>Department of Oncology, Università Politecnica delle Marche, Azienda Ospedaliera Universitaria delle Marche, Ancona, Italy. <sup>11</sup>University Hospital of Modena, Modena, Italy. <sup>12</sup>Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy. <sup>13</sup>Department of Clinical and Molecular Medicine, Sapienza University, Oncology Unit, Azienda Ospedaliera Universitaria Sant'Andrea, Rome, Italy. <sup>14</sup>Clinical Oncology Unit, Careggi University Hospital, Florence, Italy. <sup>15</sup>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. <sup>16</sup>Medical Oncology Unit, S. Carlo Hospital, Potenza, Italy. <sup>17</sup>School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK. <sup>18</sup>Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK. <sup>19</sup>Istituto di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. <sup>20</sup>Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. <sup>21</sup>Oncology Unit, ARNAS Civico Di Cristina Benfratelli Hospital, Palermo, Italy. <sup>22</sup>University of Southampton, Southampton, UK. <sup>23</sup>Unità Operativa Complessa Oncologia, Ospedale Santa Maria Goretti Latina, Latina, Italy. <sup>24</sup>Leicester Cancer Research Centre, University of Leicester, Leicester Royal Infirmary, Leicester, UK. <sup>25</sup>Candiolo Cancer Institute FPO Istituto di Ricovero e Cura a Carattere Scientifico Candiolo, Candiolo, Italy. <sup>26</sup>Azienda Socio-Sanitaria Territoriale Cremona, Cremona, Italy. <sup>27</sup>Division of Medical Oncology, ASL TO4, Ospedale Civile di Ivrea, Ivrea, Italy. <sup>28</sup>Unità Operativa Oncologia Medica, Ospedale Civile di Legnano, Azienda Socio-Sanitaria Territoriale Ovest Milanese, Legnano, Italy. <sup>29</sup>Medical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, Rome, Italy. <sup>30</sup>Medical Oncology Unit, Brescia, Italy. <sup>31</sup>Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. <sup>32</sup>Dipartimento di Tecnologie Innovative in Medicina & Odontoiatria, Università G. D'Annunzio, Chieti-Pescara, Chieti, Italy. <sup>33</sup>Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico, Fondazione G. Pascale, Naples, Italy. <sup>34</sup>Oncology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. <sup>35</sup>Beatson West of Scotland Cancer Centre, Glasgow, UK. <sup>36</sup>San Gerardo Hospital, Monza, Italy. <sup>37</sup>Division of Clinical Oncology, Azienda Socio-Sanitaria Territoriale dei Sette Laghi Varese, Varese, Italy. <sup>38</sup>Medical Oncology Unit, Ospedale del Mare, Naples, Italy. <sup>39</sup>Oncology and Palliative Care Department, Tricase Hospital, Lecce, Italy. <sup>40</sup>Luigi Sacco Hospital-Polo Universitario, Azienda Socio-Sanitaria Territoriale Fatebenefratelli Sacco, Milan, Italy. <sup>41</sup>Oncology Unit, Azienda Socio-Sanitaria Territoriale Bergamo Ovest, Treviglio, Italy. <sup>42</sup>Medical Oncology Unit, Azienda Ospedaliera di Rilievo Nazionale 'San Pio', Benevento, Italy. <sup>43</sup>Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, the Netherlands. <sup>44</sup>Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy. <sup>45</sup>Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. <sup>46</sup>These authors contributed equally: Xuhui Ma, Salo N. Ooft, Pim W. van der Helm. <sup>47</sup>These authors jointly supervised this work: Emile E. Voest, Nicola Valeri. ✉e-mail: [e.voest@nki.nl](mailto:e.voest@nki.nl); [n.valeri@imperial.ac.uk](mailto:n.valeri@imperial.ac.uk)

## Methods

### Study participants

**Discovery cohort.** The large, publicly available, real-world dataset with clinical annotation and whole-genome sequencing (WGS) by the HMF was used as the discovery cohort<sup>17</sup>. All patients who received FTD/TPI as part of their standard-of-care treatment for mCRC were identified in May 2018 (Supplementary Table 2). These patients were included in 13 academic, teaching, and regional hospitals in the Netherlands. The study was approved by the Medical Ethical Committee of the University Medical Center Utrecht and was conducted in accordance with the Declaration of Helsinki (fourth edition). All patients provided written informed consent for the collection, analysis and pseudonymized sharing of paired tumor-normal WGS data and clinical characteristics for research purposes.

**Real-world validation cohort.** For validation, we retrospectively collected data of 1,012 patients with mCRC treated with FTD/TPI as part of standard of care between April 2016 and January 2022 at 36 academic, teaching and regional hospitals across Italy and the UK (Supplementary Tables 6 and 7). The data cutoff was April 2022. Tumor *KRAS*, *NRAS* and *BRAF* genotype was investigated locally as recommended by local guidelines. Fifty-two patients with unknown *NRAS* or *BRAF* status were excluded, resulting in a final cohort of 960 patients used for all analyses. For patients from the UK, the study built on a UK National Audit<sup>24</sup> and data were handled in accordance with the Declaration of Helsinki. Formal ethical approval for data collection, analysis and pseudonymized sharing for research purposes was covered by UK Health Research Authority guidance (NHS Health Research Authority, Service Evaluation Clinical/Non-Financial Audit Usual Practice (in Public Health Including Health Protection)). For patients from Italy, data collection, analysis and pseudonymized sharing for research purposes was approved by the institutional review board of the Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico (Milano, Italy) and was conducted in accordance with the Declaration of Helsinki.

**RECOURSE trial cohort.** The RECOURSE trial design has been previously described in detail<sup>3</sup>. Briefly, the RECOURSE trial (NCT01607957) was an international double-blind, randomized, placebo-controlled, phase 3 trial comparing FTD/TPI plus best supportive care to placebo plus best supportive care. Heavily pretreated patients with refractory mCRC ( $n = 800$ ) were randomly assigned in a 2:1 ratio to receive FTD/TPI or placebo. Within this process, patients were stratified based on *KRAS* status (mutant yes/no), time between first diagnosis of metastases and randomization (<18 versus  $\geq 18$  months) and geographical region (Japan or USA, Europe and Australia). The data cutoff was at 571 deaths, in accordance with the cutoff of the primary analysis. All patients in the study provided written informed consent, as stated in the original publication<sup>3</sup>.

**Memorial Sloan Kettering Cancer Center CRC cohort.** Somatic mutation data were downloaded from the cBioPortal for cancer genomics (<http://cbioportal.org/msk-impact>) on 8 August 2017. All samples with 'GeneralTumorType' = 'Colorectal Cancer' were included (Supplementary Table 1).

**PDO cohort.** PDOs were cultured from tumor biopsies of patients with mCRC, with approval of the Medical Ethical Committee of the Netherlands Cancer Institute. We used four *KRAS*<sup>G12</sup>-mutated (SNS26: *KRAS*<sup>G12S</sup>; TUM10: *KRAS*<sup>G12V</sup>; TUM3: *KRAS*<sup>G12A</sup>; TUM52: *KRAS*<sup>G12C</sup>) and three *KRAS*<sup>WT</sup> (TUM42, TUM50, TUM65) PDOs (Supplementary Table 9). The study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent for organoid culture and collection, analysis and pseudonymized sharing of clinical characteristics for research purposes.

### End points and study objectives

In the real-world discovery analysis, we searched for genome-wide somatic variants associated with OS and time on FTD/TPI treatment as end points. In the real-world validation analysis, the primary and secondary objectives were to assess the association of *KRAS*<sup>G12</sup> mutation status with OS and PFS, respectively, both in the population as a whole and in *RAS/RAF* mutation-based subpopulations. All end points used in the real-life analyses were measured from the start of FTD/TPI treatment and evaluated at participating institutions over the treatment course according to local practice. In our reanalysis of the RECOURSE trial, we tested OS benefit and PFS benefit of FTD/TPI versus placebo as the primary and secondary end points, respectively, in subgroups defined by codon-specific *KRAS* mutation status. This was in accordance with the hierarchy of end points prespecified in the RECOURSE trial protocol; these reanalyses were prespecified in a formal data request to the sponsor of the RECOURSE study before access to the data was granted.

### Bioinformatics analysis

All genomics data of the discovery cohort was publicly available and provided by the HMF under the approved data request DR-015. WGS (median depths approximately 100 and approximately 40 for tumor and normal, respectively) and bioinformatics analysis of the discovery cohort were performed by the HMF as described previously<sup>17</sup>, with an optimized pipeline based on open-source tools freely available on GitHub (<https://github.com/hartwigmedical/pipeline5>). Somatic genomic drivers were identified as an integrated functionality of PURPLE v.2.43 (ref.<sup>17</sup>). Briefly, somatic mutations were considered drivers if they fulfilled one of the following criteria: (1) mutations in oncogenes located at—or within five bases of—known hotspots; (2) inframe indels in oncogenes with repeat count <8 repeats; (3) biallelic (that is, the WT allele is lost) nonsense, splice or indel variants in tumor suppressor genes (TSGs); and (4) mutations in oncogenes or TSGs with a sample-specific driver likelihood >80%, as calculated by PURPLE as described previously<sup>17</sup>. For this manuscript, we only considered TSG mutations to be drivers if (1) they were biallelic or (2) in the case of multiple mutations in the gene for which the summed variant ploidies exceeded the gene ploidy within the sample –0.5 (for example, the classical APC two-hit hypothesis). Amplifications were considered to be drivers if (1) they affected an oncogene with pan-cancer evidence for recurrent amplification<sup>17</sup> and (2) this oncogene had a copy number exceeding three times the sample ploidy. Deletions were considered to be drivers if (1) they affected TSGs with pan-cancer evidence for recurrent deletion<sup>17</sup> and (2) they were homozygous (absolute gene copy number <0.5).

### Statistical analysis

Median time on treatment, OS and PFS were calculated using the Kaplan–Meier method. OS and time on treatment were compared between biomarker positive versus negative patients in the discovery cohort using the exact log-rank test. In this analysis, multiple-hypothesis correction was performed using the Benjamini–Hochberg procedure. HRs and corresponding 95% CIs, and Wald test-based two-sided *P* values, were estimated from Cox regression models. The proportional-hazards assumption was tested using the methodology developed by Grambsch and Therneau<sup>25</sup>, with a significance threshold of *P* = 0.05; categorical covariates were modeled as stratification factors (rather than covariates) where appropriate to prevent assumption violations. 'Unadjusted' Cox regression analyses of the real-world validation cohort were performed in a univariate manner. 'Adjusted' Cox regression analyses of the real-world validation cohort were stratified for ECOG performance status (0–1 versus  $\geq 2$ ) and adjusted for seven additional covariates: time since diagnosis of first metastases (<18 versus  $\geq 18$  months); geographical region (UK versus Italy); age (<65 versus  $\geq 65$  years); sex; sidedness (left versus right); previous surgery (yes versus no); and peritoneal disease at the start of FTD/TPI treatment (yes versus no). For the RECOURSE

trial-based analyses, ‘unadjusted’ Cox regression was stratified for two stratification factors of the trial: time since diagnosis of first metastases (<18 versus  $\geq 18$  months) and geographical region (Japan versus the USA, Europe and Australia). The third stratification factor of the trial, *KRAS* mutation status, was omitted because of high collinearity with our variables of interest (codon-specific *KRAS* status). For ‘adjusted’ RECURSE trial-based analyses, we used stratified, multivariate Cox regression to adjust for eight prognostic factors on top of the two stratification factors used in the unadjusted analyses. These included: age (<65 versus  $\geq 65$  years); sex; ECOG performance status (0 versus 1); primary site of the disease (colon versus rectum); disease refractory to fluoropyrimidine as part of the last previous regimen (yes versus no); previous use of regorafenib; number of previous regimens (2, 3 or  $\geq 4$ ); and number of metastatic sites (1–2 versus  $\geq 3$ ). The rationale behind the selection of covariates for multivariate Cox regression is specified below. No subsequent covariate selection was performed; hence, all eight covariates plus the two stratification factors were included in all multivariate models of RECURSE trial data. None of these variables were predictive of FTD/TPI benefit in the RECURSE trial ( $P > 0.20$  for all variables)<sup>3</sup>. Dose–response curves were fitted using Prism v.9.0.0 (GraphPad Software) on  $\log_2$ -transformed FTD concentration values versus viability; the resulting fitted curves were then used to calculate  $IC_{50}$  values. Baseline characteristics were compared by Fisher’s exact test for categorical variables with two levels and by chi-squared test in the case of more than two levels. All reported  $P$  values are two-sided. In the main text and figures, all  $P$  values smaller than 0.001 were reported as <0.001. RECURSE trial data-based survival analyses were performed on the intention-to-treat population and were prespecified in a formal data request before access to the data was granted.

### Candidate biomarker selection for the discovery cohort

The procedure for the selection of candidate biomarkers was as follows. Somatic genomic driver alterations (mutations and copy number alterations) were included as candidate biomarkers at increasingly specific ‘levels’: (1) gene-level biomarkers, for example, ‘*APC* alteration’, which could either be by mutation or copy number alteration; (2) variant class-level biomarkers, for example, ‘*APC* mutation’ or ‘*APC* deletion’; (3) codon-level biomarkers, for example, ‘*APC* codon 1450 mutation’; and (4) amino acid change-specific biomarkers, for example, ‘*APC* p.Thr562Met mutation’. In cases where biomarkers of different levels showed complete redundancy, only the most specific level was included. For example, all *KRAS* alterations in the cohort were mutations leading to complete redundancy between ‘*KRAS* alteration’ and ‘*KRAS* mutation’. Hence, *KRAS* mutation was selected as the most specific level and included as a candidate biomarker, whereas *KRAS* alteration was excluded. All candidate biomarkers occurring in at least five patients in the discovery cohort were tested for association with treatment outcomes. Supplementary Table 3 provides a comprehensive overview of the frequencies of all candidate biomarkers identified in our cohort.

### Variable selection for multivariate Cox regression

**Real-world validation cohort.** We selected eight variables for multivariate (adjusted) Cox proportional-hazards modeling of the real-world validation cohort. In this process, we aimed to harmonize the selection as much as possible to the variables used in the Cox regression modeling of the RECURSE trial-based data (see below), with some alterations.

The ECOG performance status (0–1 versus  $\geq 2$ ) was used as a stratification factor because this variable violated the proportional-hazards assumption when modeled as a covariate. Furthermore, we adjusted for seven additional covariates: time since diagnosis of first metastases (<18 versus  $\geq 18$  months); geographical region (UK versus Italy); age (<65 versus  $\geq 65$  years); sex; sidedness (left versus right); previous surgery (yes versus no); and peritoneal disease at the start of FTD/TPI treatment (yes versus no). Sidedness was used instead of primary site of the disease (colon versus rectum, as used in the RECURSE

trial-based analyses), because sidedness was most strongly associated with OS and only one of these two variables could be included due to high collinearity. Due to data unavailability for the real-world validation cohort, we were unable to factor in if the disease was refractory to fluoropyrimidine as part of the last previous regimen, previous use of regorafenib, the number of previous regimens and the number of metastatic sites in the analyses. In RECURSE trial-based analyses, none of these factors were predictive and only the latter variable was prognostic for OS. Instead, based on significant (univariate) associations with OS in the real-world validation cohort, we decided to add the two variables ‘previous surgery’ and ‘peritoneal disease at the start of FTD/TPI treatment’ to our selection of covariates, although these data were unavailable for the RECURSE trial dataset.

**RECURSE trial-based analyses.** We selected ten variables for multivariate (adjusted) Cox proportional-hazards modeling of RECURSE trial data.

This selection included all factors prespecified in the RECURSE trial study protocol, except *KRAS* status and ethnicity, totaling eight prespecified factors: time since diagnosis of first metastases (<18 versus  $\geq 18$  months (stratification factor of the study)); geographical region (Japan versus the USA, Europe and Australia; stratification factor of the study); age (<65 versus  $\geq 65$  years); sex; ECOG performance status (0 versus 1); primary site of the disease (colon versus rectum); number of previous regimens (2, 3 or  $\geq 4$ ); and number of metastatic sites (1–2 versus  $\geq 3$ ). *KRAS* status was excluded because of collinearity with our variables of interest (*KRAS*<sup>G12</sup> mutation, *KRAS*<sup>G13</sup> mutation, *KRAS*<sup>WT</sup>). Ethnicity was excluded for two reasons. First, the sponsor of the RECURSE trial could not share the original ethnicity data for privacy reasons because the number of Black participants (nine patients) was below a predefined threshold put in place to prevent patient reidentification. For this reason, the ethnicity item has been modified to a quasi-identifier of ‘Asian’ versus ‘Other’ (White or Black). In the RECURSE trial, the original ethnicity variable was not significantly prognostic or predictive for OS<sup>3</sup>. Second, the modified ethnicity variable showed high collinearity (and hence redundancy) with the included factor ‘geographical region’ because 266 out of 266 (100%) of participants from the ‘Asia’ region had the ‘Asian’ ethnicity and 522 out of 534 (98%) of participants from the USA, Europe and Australia regions had the ‘Other’ (which included Black and White) ethnicity.

Next, we included two additional factors in our multivariate models: (1) disease refractory to fluoropyrimidine as part of the last previous regimen; and (2) previous use of regorafenib. These factors were not prespecified in the RECURSE trial protocol for multivariate analyses but were used for the subgroup analyses reported by Mayer et al.<sup>3</sup>. We decided to include these pretreatment-related factors in our multivariate models because patients with *KRAS* mutant tumors showed significant differences regarding their pretreatment profiles as compared to patients with *KRAS*<sup>WT</sup> tumors. Patients with *KRAS* mutant tumors were more often refractory to fluoropyrimidine as part of their last previous regimen and were less heavily pretreated than patients with *KRAS*<sup>WT</sup> (Table 2).

*BRAF* mutation status was not included in our selection because this information was missing for 676 out of 800 (85%) patients. Subgroup analysis of the population with *BRAF* mutant tumors was not possible because *BRAF* mutations were detected in only eight patients.

### Organoid and cell line cultures and drug assays

PDOs were cultured, expanded and assayed as described previously<sup>22</sup>. FTD (catalog no. S1778, Selleckchem) and 5-FU (catalog no. S1209, Selleckchem) were reconstituted in DMSO (catalog no. D2650, Sigma-Aldrich) at a stock concentration of 50 mM. PDOs were exposed to a two-step, eightfold dilution of FTD (range = 0.781–200  $\mu$ M) for 11 d or to 5-FU for 6 d in a two-step, eightfold dilution (range = 0.781–200  $\mu$ M). Culture medium and FTD were refreshed every 3–4 d.

**Table 3 | Statistical methods and associated software**

Statistical method	Programming language	Package	Version	Function
Kaplan–Meier method	R v.3.6.1	survminer	0.4.6	surv_median
Kaplan–Meier curve plotting	R v.3.6.1	survminer	0.4.6	ggsurvplot
Exact log-rank test	R v.3.6.1	coin	1.3.1	logrank_test (distribution='exact')
Cox regression	R v.3.6.1	survival	3.2–7	coxph
Proportional-hazards assumption testing	R v.3.6.1	survival	3.2–7	cox.zph
Wilcoxon rank-sum test	Python 3	scipy	1.4.1	stats.ranksums
Fisher's exact test	Python 3	scipy	1.4.1	stats.fisher_exact
Chi-squared test	Python 3	scipy	1.4.1	stats.chi2_contingency

The isogenic cell lines were assayed with FTD and 5-FU in a similar fashion, shortening the assay duration to 3 d. The used concentrations were adjusted to include more data points of lower concentrations (range = 0.1 nM, 0.5 nM, 1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10  $\mu$ M, 20  $\mu$ M, 50  $\mu$ M, 200  $\mu$ M, 500  $\mu$ M). The readout was performed using the MTT Assay Kit for Cell Proliferation (catalog no. ab211091, Abcam); culture medium was replaced with 100  $\mu$ l of a 1:1 mix of MTT reagent with serum-free RPMI1640 (catalog no. 21875034, Gibco), which was replaced by 150  $\mu$ l MTT solvent after incubation, according to the manufacturer's protocol. Then, absorbance was measured at OD<sub>590 nm</sub> on an Infinite 200 Pro plate reader (Tecan Life Sciences).

#### Isogenic cell line construction: Colo320 *KRAS*<sup>G12D</sup> knock in

Single-guide RNA oligonucleotide sequences were designed on Chop-Chop (<http://chopchop.cbu.uib.no/#>). CRISPR–Cas9 CRISPR RNA (crRNA) (5'-CUUGUGGUAGUUGGAGCUGG-3') and trans-activating crRNA (tracrRNA) (catalog no. 1072532), Cas9 Nuclease V3 (catalog no. 1081058) and HDR Donor Oligo (5'-ATTCTGAATTAGCTGTATCGTCAAGGCACTCTTGCCCTACGCCGTCAGCTCCCACTACCACAAGTTTATATTTCAGTCATTTTCAGC-3') were purchased from Integrated DNA Technologies. Briefly, guide RNA (gRNA) complexes were formed as described previously<sup>26</sup> by combining equal amounts of crRNA (160  $\mu$ M in stock) and tracrRNA (160  $\mu$ M in stock) in Duplex Buffer (cat no. 11-01-03-01, Integrated DNA Technologies) and heating the oligonucleotides to 95 °C, followed by slowly cooling to room temperature. Cas9 nuclease was then added (the molar ratio of crRNA:Cas9 nuclease was 1:0.5) to the gRNA complexes, followed by 15-min incubation at room temperature. The Cas9 ribonucleoprotein (ctRNP) complexes were then stored on ice until use. DNA HDR templates were prepared by diluting the HDR Donor Oligo stock to 10  $\mu$ M in nuclease-free water. Electroporation was performed by using the 4D-Nucleofector X Unit (catalog no. AAF-1003X, Lonza) according to the manufacturer's instructions. For each sample, 2  $\times$  10<sup>5</sup> cells were resuspended in Ingenio Electroporation Solution (catalog no. MIR 50111, Mirus Bio). Per reaction, 2.5  $\mu$ M ctRNP and 0.5  $\mu$ M HDR template were added to the cell suspension. We next pipetted 20  $\mu$ l of each sample into individual wells of 16-well Nucleocuvette Strips (catalog no. AXP-1004, Lonza) and ran the program CM-137. After electroporation, cells were sorted by FACS and single cells were cultured in 96-well plates for up to two weeks. For single-cell clones, the presence of the *KRAS*<sup>G12D</sup> mutation was then confirmed by Sanger sequencing.

#### Western blot analysis

Western blot analysis was performed on the isogenic cell lines and PDOs treated with FTD or 5-FU, at different concentrations, for 24 h (cell lines) or 48 h (PDOs). For PDOs (but not for the isogenic cell lines), the extracellular matrix was removed by incubating with 2 mg ml<sup>-1</sup> type II dispase (catalog no. D4693, Sigma-Aldrich) for 10 min at 37 °C. Cells were washed with PBS and lysed in RIPA Lysis and Extraction Buffer (catalog no. 89901, Thermo Fisher Scientific), supplemented with

Phosphatase Inhibitor Cocktail (catalog no. 78420, Thermo Fisher Scientific) and Halt Protease Inhibitor Cocktail (catalog no. 87786, Thermo Fisher Scientific). Protein concentration was determined using Coomassie Brilliant Blue G-250 (catalog no. 1610803, Bio-Rad Laboratories). Protein samples were run on NuPAGE 4–12% Bis-Tris Gels (catalog no. NP0323BOX, Thermo Fisher Scientific), transfer was performed using the iBlot 2 Gel Transfer Device (catalog no. IB21001, Thermo Fisher Scientific) and compatible iBlot Transfer Stack; nitrocellulose (catalog no. IB301002, Thermo Fisher Scientific) membranes were used. Membranes were blocked in 5% BSA (catalog no. 10735094001, Sigma-Aldrich) in PBS plus 0.2% Tween-20 (catalog no. P1379-1L, Sigma-Aldrich) for 1 h, then incubated with primary antibodies in 5% BSA in PBS and Tween-20. As primary antibodies, we used anti-phospho-Histone H2A.X (Ser139, catalog no. 05-636, Sigma-Aldrich) and anti-HSP 90 $\alpha$ / $\beta$  (catalog no. sc-13119, Santa Cruz Biotechnology), which were diluted 1:1,000 in PBS with 5% BSA. The secondary antibody (anti-mouse IgG, HRP-linked antibody, catalog no. 7076, Cell Signaling Technology) was diluted 1:1,000 in 5% BSA in PBS and Tween-20. The blots were incubated with Clarity Max Western ECL Substrate (catalog no. 1705062, Bio-Rad Laboratories) and the luminescence signal was imaged using the ChemiDoc Imaging System (catalog no. 17001401, Bio-Rad Laboratories).

#### Colony formation assay

Cells were seeded into six-well plates (1.5–2  $\times$  10<sup>4</sup> cells per well) and cultured in the presence of drugs at the indicated concentrations. For each cell line, cells cultured using different conditions were fixed in methanol (catalog no. 32213, Honeywell) and stained with 0.1% crystal violet solution (catalog no. V5265, Sigma-Aldrich).

#### Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the article. Authors had full access to all the data and had the final responsibility to submit for publication.

#### Statistical methods and associated software

The statistical methods and associated packages used in this study are summarized in Table 3.

#### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

#### Data availability

The somatic mutation data of the MSKCC cohort are freely available via the cBioPortal for cancer genomics (<http://cbioportal.org/msk-impact>); patient identifiers are provided in Supplementary Table 1. The sequencing data of the HMF cohort (discovery cohort) can be accessed through the Hartwig Medical Foundation upon approval of

a research access request (<https://www.hartwigmedicalfoundation.nl/en/data/data-access-request>). The patient identifiers, patient-level clinical outcome data and biomarker status of all patients in this cohort are provided in Supplementary Table 2. The original data used in all analyses of the real-world validation cohort can be found in Supplementary Table 7. The RECURSE trial data can be accessed upon approval of a data request at Servier (<https://clinicaltrials.servier.com/data-request-portal/>). Source data are provided with this paper.

## Code availability

The bioinformatics for the WGS data of the discovery cohort were performed with an optimized pipeline based on open-source tools; this is freely available on GitHub (<https://github.com/hartwigmedical/pipeline5>).

## References

24. Stavraka, C. et al. Trifluridine/tipiracil in metastatic colorectal cancer: a UK multicenter real-world analysis on efficacy, safety, predictive and prognostic factors. *Clin. Colorectal Cancer* **20**, 342–349 (2021).
25. Grambsch, P. M. & Therneau, T. M. Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika* **81**, 515–526 (1994).
26. Jacobi, A. M. et al. Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes. *Methods* **121–122**, 16–28 (2017).

## Acknowledgements

We thank Servier for sharing the RECURSE trial dataset and acknowledge all contributors to this trial. We thank the Hartwig Medical Foundation, the Center for Personalized Cancer Treatment and all participating centers for the generation of the discovery dataset. We thank the Memorial Sloan Cancer Center for generating the data used in this manuscript. We also thank the statistics department of the Netherlands Cancer Institute for support with the analyses and G. Arrivi and M. Roberto (Sant'Andrea Hospital Rome) for their support in data acquisition. We thank A. Bardelli and his team for sharing the isogenic SW48 models. E.E.V. and L.F.A.W. were supported by funding from the Oncode Institute. D.J.P. is supported by grant funding from the Wellcome Trust Strategic Fund (no. PS3416), the Foundation for Liver Research and the Associazione Italiana per la Ricerca sul Cancro (AIRC MFAG grant no. 25697); he acknowledges support from the National Institute for Health and Care Research (NIHR) Imperial Biomedical Research Centre, the Imperial Experimental Cancer Medicine Centre (ECMC) and the Imperial College Tissue Bank. N.V. was supported by Cancer Research UK (grant nos. A18052 and A26815), the NIHR Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, the European Union FP7 (grant no. CIG 334261) and the Katherine and Douglas Longden Chair in Oncology at Imperial College London. N.V. also acknowledges infrastructural support from the ECMC at Imperial College London.

## Author contributions

J.v.d.H., S.N.O., N.V. and E.E.V. conceptualized the study. J.v.d.H., M.G., A.C. and L.R.H. curated the clinical data. L.R.H., D.J.P., K.S., L.S., G.T., I.V.Z., S.L., R.G., R.B., F.G., V.M., F.M., L.A., G.R., C.S., P.R., M.G.R., M.P., C. Morelli, T.I., F.Z., A.T., E.F., M.R., I.D., M.C., C. Messina, M.L., A. Petrillo, M.D.T., N.Z., O.G., J.G., R.L., S.M.G., A. Parisi, E.T., N.L.V., F.P. and V.R. acquired the clinical data. J.v.d.H. was responsible for the bioinformatics. J.v.d.H., S.N.O., X.M., P.W.v.d.H., S.M. and E.E.V. designed the in vitro experiments. S.N.O., X.M. and P.W.v.d.H. carried out the in vitro experiments. J.v.d.H., S.N.O., X.M. and P.W.v.d.H. carried out the formal analysis. E.E.V. acquired the funding. J.v.d.H., S.N.O., X.M., P.W.v.d.H., L.F.A.W., A.C., N.V. and E.E.V. devised the methodology. L.F.A.W., N.V. and E.E.V. supervised the study. J.v.d.H. and S.N.O. wrote the original draft. All authors contributed to reviewing and editing the final manuscript.

## Competing interests

E.E.V. reports research grants from Roche, Pfizer, GSK, Novartis, Merck, Bristol Myers Squibb, AstraZeneca, Amgen, Bayer, Sanofi, Seagen, Janssen, Eisai, Ipsen and Lilly. He is a founder, strategic advisor and shareholder of MOSAIC Therapeutics and nonexecutive, independent director and shareholder of Sanofi, all outside the submitted work. L.F.A.W. reports grants from Genmab, outside the submitted work. A.C. received grant consultancy fees from MSD, AstraZeneca, Oncoc4 and IQVIA. He also declares speaker's fees from Eisai and AstraZeneca. A.P. received personal fees from Lilly, Servier, Merck, Amgen, Bristol Myers Squibb and MSD. A.T. declares speaker bureau fees from Bristol Myers Squibb and Servier. C.S. received honoraria from the speaker bureau at Servier. D.J.P. received lecture fees from Viiv Healthcare, Bayer Healthcare, Bristol Myers Squibb, Roche, Eisai and the Falk Foundation, travel expenses from Bristol Myers Squibb and Bayer Healthcare, consulting fees for Mina Therapeutics, H3B, Eisai, Roche, DaViverra, Mursla, Exact Sciences, Avamune and AstraZeneca and research funding (to institution) from MSD, Bristol Myers Squibb and GSK. F.G. received honoraria for speaker/advisory roles from Servier, Lilly, IQVIA, Merck Serono, Bayer, Amgen and Bristol Myers Squibb outside the present work. F.M. received fees from the speaker bureaux of Servier, Amgen, Novartis, MSD and Merck. G.T. took part in the advisory boards for Bristol Myers Squibb, AstraZeneca, MSD, Merck and Servier. J.G. received honoraria for educational events organized by Servier. L.S. received speaker and consultancy fees from MSD, AstraZeneca, Servier, Bayer, Merck, Amgen and Pierre-Fabre. M.G.R. received consultancy fees from Roche. M.G. received grants and advisory board fees from Merck, Servier, Lilly, Amgen and Italfarmaco. N.L.V. received fees and honoraria from Eisai, MSD, Roche, Novartis, AstraZeneca, GSK, Pfizer, Gentili and Lilly. N.V. received honoraria from Merck Serono, Pfizer, Bayer, Lilly and Servier, consultancy fees from BenevolentAI and grants (institutional) from Roche and BenevolentAI. N.Z. declares personal fees from Bayer and Eisai. O.G. reports consulting fees from Eisai, Lilly, MSD and Seagen and payment or honoraria for lectures, presentations, speaker bureaux fees, manuscript writing or educational events from Novartis, Lilly and Eisai. P.R. received grants from Bayer and Sanofi, honoraria for advisory boards from AstraZeneca, Eisai, Servier and Sirtex, speaking fees from Amgen, Boston Scientific, HMP Education, Eisai, Roche and Servier and travel conference support from Bayer, Roche, Ipsen and Servier. R.G. took part in advisory boards for Merck, Amgen, Servier and Bayer. R.B. declares consultancies, advisory board roles and/or institutional donations from AstraZeneca, Boehringer Ingelheim, Novartis, MSD, Otsuka, Lilly, Roche, Amgen, GSK and Eisai. T.I. received honoraria for educational symposia run by Servier. All other authors declare no competing interests.

## Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41591-023-02240-8>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41591-023-02240-8>.


**Correspondence and requests for materials** should be addressed to Emile E. Voest or Nicola Valeri.

**Peer review information** *Nature Medicine* thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editors: Javier Carmona and Joao Monteiro, in collaboration with the *Nature Medicine* team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).




**Extended Data Fig. 1** | Codon-specific *KRAS* mutation frequencies in mCRC (MSKCC cohort<sup>1</sup>). WT: wild type; DM: double mutation.




Extended Data Fig. 2 | Overview of the study and the cohorts used in the analyses.






**Extended Data Fig. 3 | Discovery of KRAS<sup>G12</sup> mutation status as potential biomarker of outcome of FTD/TPI treatment in mCRC. a** dot plot showing the associations of candidate genomic biomarkers to time on FTD/TPI treatment in the discovery cohort (n = 37). The exact log-rank test statistic ( $\theta$ ) for treatment discontinuation for patients with the candidate biomarker versus those without is plotted against the Benjamini-Hochberg-corrected false

discovery rate (FDR). The red line indicates the 5% FDR significance threshold. **b** A Kaplan-Meier curve of time on treatment in the discovery cohort, for patients without (black) or with (red) a KRAS<sup>G12</sup> mutation. Censoring events are indicated by vertical bars on the corresponding curve. Dotted lines indicate the median overall survival. The table underneath the plot denotes the numbers at risk. The exact log-rank test-based two-sided P value is shown.




**Extended Data Fig. 4 | Associations of KRAS<sup>G12</sup> mutations with progression-free survival of 960 patients with mCRC receiving FTD/TPI treatment in a real-world setting.** Kaplan-Meier curves of progression-free survival in the full population (left), RAS/RAF mutant population (middle), and KRAS exon 2 mutant population (right), stratified based on the presence (red) or absence (black) of a KRAS<sup>G12</sup> mutation. Censoring events are indicated by vertical bars on the

corresponding curve. Dotted lines indicate the median overall survival. The table underneath each plot denotes the numbers at risk. Two-sided Wald test-based *P* values are shown. \*Unadjusted: By univariate Cox regression. \*\*Adjusted: By stratified, multivariate Cox regression, adjusted for eight baseline characteristics (see methods). Note that none of the Cox regression models significantly violated the proportional hazards assumption, despite crossing survival curves.




**Extended Data Fig. 5 | Kaplan-Meier curves of overall survival of KRAS<sup>G12</sup>-mutated, KRAS<sup>G13</sup>-mutated and KRAS<sup>WT</sup> patients in the placebo arm of the RECURSE trial.** Censoring events are indicated by vertical bars on the corresponding curve. Dotted lines and corresponding annotation indicate the

median overall survival. The table underneath the plot denotes the numbers at risk. Cox regression-based hazard ratio (HR), 95% confidence interval (CI) and two-sided Wald test-based *P* values are plotted for pairwise comparisons.




**Extended Data Fig. 6 | Forest plot of hazard ratios and 95% CI for overall survival with FTD/TPI versus placebo, for the KRAS<sup>G12</sup>-mutated population in amino acid change-based subgroups.** The five most frequent KRAS<sup>G12</sup> amino acid changes are shown as individual subgroups. KRAS<sup>G12Other</sup> comprises all patients with KRAS<sup>G12</sup> mutations that induce amino acid changes other than these

five most frequent changes. We excluded 21 patients with KRAS<sup>G12</sup> mutations for which data on the amino acid change was missing. Two-sided Wald test-based *P* values for interaction (as calculated using Cox regression) indicate if the survival benefit of FTD/TPI treatment versus placebo was significantly different for a specific subgroup, as compared to all patients with other KRAS<sup>G12</sup> mutations.



**Extended Data Fig. 7 | Progression-free survival in codon-specific *KRAS* mutation-based subgroups in the RECOURSE trial.** Forest plot of hazard ratios for progression or death and 95% CI, stratified based on codon-specific *KRAS* mutation status. Two-sided Wald test-based *P* values for interaction (as calculated using Cox regression) indicate if the survival benefit of FTD/TPI treatment versus placebo was significantly different between subgroups, for

which pairwise comparisons are indicated by the square brackets. \*Unadjusted: stratified for two stratification factors of the trial (time from diagnosis of metastases [ $<18$  mo versus  $\geq 18$  mo] and region [Japan versus United States, Europe, and Australia]). \*\*Adjusted: adjusted by the two stratification factors used in unadjusted analysis, plus eight additional baseline characteristics (see methods). NE: not estimable.



**Extended Data Fig. 8 | Growth rate of patient-derived mCRC organoids versus KRAS-based subgroup or *in vitro* trifluridine sensitivity.** **a** The ( $\log_2$ ) *in vitro* growth rate of patient-derived mCRC organoids in the untreated condition is plotted as stratified per *KRAS* mutation-based subgroup. Box center lines, box ranges, whiskers, and dots indicate medians, quartiles, 1.5 interquartile ranges, and data points of individual organoid lines, respectively. Colors of dots denote the organoid line, as shown in the legend. Two-sided two sample

*t*-test-based *P* value is shown. **b** Half maximal inhibitory concentrations (IC50;  $\log_2$ ) for trifluridine of  $KRAS^{WT}$  (black;  $n=3$ ) and  $KRAS^{G12}$  (red;  $n=4$ ) organoid lines (x-axis), is plotted against the ( $\log_2$ ) *in vitro* growth rate of patient-derived mCRC organoids in the untreated condition (y-axis). The linear fit and bootstrapping-obtained 95% confidence interval of the regression estimate is denoted in dark and light blue, respectively. Pearson and Spearman correlation coefficients and corresponding *P* values are shown.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection	Bioinformatics for whole genome sequencing data were performed as previously described, with an optimized pipeline based on open source tools, including PURPLE v2.43 for somatic driver calling, which is freely available on GitHub ( <a href="https://github.com/hartwigmedical/pipeline5">https://github.com/hartwigmedical/pipeline5</a> ). For other data, did not use specific computer code for collection.
Data analysis	Kaplan-Meier method: R package = survminer 0.4.6; function = surv_median Kaplan-Meier curve plotting: R package = survminer 0.4.6; function = ggsvrplot Cox regression: R package = survival 3.2.7; function = coxph Cox proportional hazards assumption testing: R package = survival 3.2.7; function = cox.zph Fisher's exact test: Python 3 package = scipy 1.4.1; function = stats.fisher_exact Chi2 test: Python 3 package = scipy 1.4.1; function = stats.chi2_contingency Wilcoxon rank sum test = scipy 1.4.1; function = stats.ranksums Dose-response curve fitting: Graphpad Prism 9.0.0

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

### Discovery cohort HMF

Sample identifiers and patient-level biomarker and clinical outcome data are available in Supplementary Table 2. Raw and processed genomics data are freely available at Hartwig Medical Foundation through standardized procedures and request forms (<https://www.hartwigmedicalfoundation.nl/en/data/data-access-request>).

### Real-World validation cohort

The original data used in all analyses of the real-world validation cohort can be found Supplementary Table 7.

### RECURSE trial

The RECURSE trial data can be accessed upon approval of a data request at Servier (<https://clinicaltrials.servier.com/data-request-portal/>).

### MSKCC Colorectal Cancer Cohort

Somatic mutation data of the MSKCC cohort are freely available via the cBioportal for cancer genomics (<http://cbioportal.org/msk-impact>) and patient identifiers are provided in Supplementary Table 1.

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

### Reporting on sex and gender

Throughout the manuscript, we report sex as an biological attribute, which was collected through self reporting. Sharing of patient-level, pseudonymized clinical data, including sex, for research purposes was covered by the informed consents of the individual studies and local legislation.

### Population characteristics

#### Discovery cohort HMF

Patients with advanced or metastatic cancer for whom there is an indication for any systemic treatment were included in the HMF database as part of the CPCT-02 (NCT01855477) clinical study. We included all patients in the HMF database who received FTD/TPI as part of their standard-of-care treatment for advanced/metastatic, histologically proven, colorectal carcinoma, which were identified in the HMF database in May 2018. The median age was 62 years (IQR 59-68), 38% was (self-reported) female and 62% male, and the percentage of patients with KRAS G12 and other KRAS mutations were 54% and 11%, respectively. All patients received FTD/TPI treatment as part of standard-of-care. As FTD/TPI is approved as final line therapy, these were all late-stage patients.

#### Real-World Cohort (UK and Italy)

Retrospective collection of all sequential patients with advanced/metastatic, histologically proven, colorectal carcinoma undergoing treatment with FTD/TPI following progression to prior lines of standard chemotherapy, with known codon-specific RAS/RAF status known between November 2016 and March 2022. As reported in Table 1, the median age was 64 years (IQR 56-71), 41% was (self-reported) female and 59% male, 72% and 28% were diagnosed with colon and rectum cancer, respectively, and the percentage of patients with KRAS G12, KRAS G13, KRAS other, NRAS and BRAF mutations were 36%, 9.0%, 5.5%, 6.4%, and 3.3%, respectively. All patients received FTD/TPI treatment as part of standard-of-care. As FTD/TPI is approved as final line therapy, these were all late-stage patients.

#### RECURSE trial (population description from the original publication, by Mayer et al, NEJM 2015)

"Baseline demographic and disease characteristics were well balanced between the two study groups (Table 1). All the patients had received prior chemotherapy regimens containing a fluoropyrimidine, oxaliplatin, and irinotecan; all but one patient (in the placebo group) had received bevacizumab. All but two patients (one patient in each study group) with KRAS wild-type tumors had received cetuximab or panitumumab. Regorafenib, an oral multikinase inhibitor, became available for the management of previously treated colorectal cancer during the course of the study; 17% of the patients in the TAS-102 group, as compared with 20% of those in the placebo group, had received this drug. A large percentage of patients in both study groups — 93% of patients receiving TAS-102 and 90% of those receiving placebo — had disease that had been refractory to fluoropyrimidines when they were last exposed to this class of drugs. Moreover, 58% of the patients receiving TAS-102 and 54% of the patients receiving placebo had disease that had been refractory to fluoropyrimidine when that drug was administered as part of their last treatment regimen before study entry."

"Patients with biopsy-documented adenocarcinoma of the colon or rectum were eligible for participation in the study if they had received at least two prior regimens of standard chemotherapies, which could have included adjuvant chemotherapy if a tumor had recurred within 6 months after the last administration of this therapy; if they had either tumor progression within 3 months after the last administration of chemotherapy; or if they had had clinically significant adverse events from standard chemotherapies that precluded the readministration of those therapies. Eligibility also required knowledge of tumor status with regard to KRAS (i.e., wild-type or mutant), as reported by investigators. Patients were also required to have received chemotherapy with each of the following agents: a fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and — for patients with KRAS wild-type tumors — cetuximab or panitumumab. In addition, patients had to be 18 years of age or older; have adequate bone-marrow, liver, and renal function; and have an Eastern Cooperative Oncology Group (ECOG) performance



## Recruitment

status of 0 or 1 (on a scale of 0 to 5, with 0 indicating no symptoms, 1 indicating mild symptoms, and higher numbers indicating increasing degrees of disability)."

## Discovery cohort HMF

Patients with advanced or metastatic cancer for whom there is an indication for any systemic treatment were included in the HMF database as part of the CPCT-02 (NCT01855477) clinical study. The CPCT-02 study, patients were included by 41 academic, teaching and general hospitals across The Netherlands and collected material and clinical data by standardized protocols. Metastatic cancer patients were asked to participate in the studies in any of the 41 participating hospitals. Recruitment involved hundreds of medical specialists and research nurses which minimizes self-selection biases. Recruitment was independent on tumor type. An important requirement for participation was the ability to safely undergo a tumor biopsy. Health conditions and lesion site related risk could therefore have resulted in exclusion of patients.

## Real-world validation cohort

As per above

## RECURSE trial (recruitment details from the original publication, by Mayer et al, NEJM 2015)

"Between June 17, 2012, and October 8, 2013, a total of 1002 patients were screened for eligibility, of whom 800 underwent randomization, with 534 assigned to receive TAS-102 and 266 assigned to receive placebo (intention-to-treat population) (details regarding the disposition of patients are provided in Fig. S1 in the Supplementary Appendix, available at NEJM.org). Treatment was initiated in 798 patients, with 533 receiving TAS-102 and 265 receiving placebo (safety-analysis population). All treated patients received their assigned study drug according to the randomization schema, and 760 could be evaluated for assessment of tumor response (tumor-response population)."

## Ethics oversight

## HMF discovery cohort

The study was approved by the Medical Ethical Committee of the University Medical Center Utrecht and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent for collection, analysis and pseudonymized sharing paired tumor-normal whole genome sequencing data and clinical characteristics for research purposes.

## Real-world validation cohort

For patients included from the UK, the study built on a UK National Audit (Stavraka et al. Clin Colorectal Cancer. 2021 Dec;20(4):342-349) and data were handled in accordance with the Declaration of Helsinki. Formal ethical approval for data collection, analysis and pseudonymized sharing for research purposes was covered by UK Health Research Authority guidance (NHS Health Research Authority. Service Evaluation Clinical/Non Financial Audit Usual Practice [in Public Health Including Health Protection]. London: NHRA). For patients included in Italy, data collection, analysis and pseudonymized sharing for research purposes was approved by the Institutional Review Board of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy and was conducted in accordance with the Declaration of Helsinki.

## RECURSE trial (from the original publication, by Mayer et al, NEJM, 2015)

"The review board at each participating institution approved the study, which was conducted according to the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent."

## Patient-derived organoid (PDO) cohort

The study was approved by the Medical Ethical Committee of the Netherlands Cancer Institute and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent for organoid culture and collection, analysis and pseudonymized sharing of clinical characteristics for research purposes.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

## Sample size

A priori sample size calculations were not performed. Sample sizes were determined by the max amount of patients/samples with available data.

Discovery cohort: All patients in the HMF database who received FTD/TPI as part of their standard-of-care treatment for mCRC were identified in May 2018.

Real-World Cohort (UK and Italy): Clinical pathological and molecular data of all the sequential patient treated with FTD/TPI at 35 centers in Italy and UK between between November 2016 and March 2022 were retrieved accessing electronic patients records (n=1012). 52 patients were excluded from the analysis as explained below, leading the final number of analyzed cases to n=960.

	<p>RECOURSE trial: All 800 included patients.</p> <p>MSKCC Colorectal Cancer Cohort: All samples with 'GeneralTumorType' = 'Colorectal Cancer' were included. TCGA Colorectal Cancer Cohort: All samples with 'Primary Site' = 'Colon' or 'Rectum' were included.</p>
Data exclusions	<p>Discovery cohort: No exclusions</p> <p>RECOURSE trial: No exclusions</p> <p>Real-World Cohort (UK and Italy): 52 patients were excluded as NRAS and/or BRAF status was not available.</p> <p>MSKCC Colorectal Cancer Cohort: No exclusions</p> <p>TCGA Colorectal Cancer Cohort: Only patients with available consensus molecular subtypes (CMS) were considered</p>
Replication	<p>The main finding of the manuscript that KRAS G12 mutations are associated with reduced OS in patients with mCRC upon treatment with FTD/TPI was found in a discovery cohort, replicated in a large real-world cohort and in the RECOURSE trial. The RECOURSE trial-based analysis showed that this was based on a predictive effect. This RECOURSE trial-based analysis was prespecified in a formal data request before access to the data was granted, which minimizes potential biases. The finding that KRAS G13 patients have improved OS upon treatment with FTD/TPI was discovered in the large real-world cohort, as these patients were absent in the smaller discovery cohort. This finding was then replicated with re-analysis of the RECOURSE trial (also pre-specified in our formal data request), which showed that this was based on a predictive effect.</p> <p>In vitro results:</p> <p>The colony formation assays (Figure 4A-B) were independently repeated three times with similar results.</p> <p>FTD/TPI sensitivity testing of isogenic cells lines (Figure 4C-D) was independently repeated four times with similar results.</p> <p>FTD/TPI sensitivity testing of KRAS wild type organoid lines (Figure 4E-F) was independently repeated three times with similar results.</p> <p>FTD/TPI sensitivity testing of KRAS G12 mutant organoid lines (Figure 4E-F) was independently repeated four times with similar results.</p> <p>Western blot analysis of SW48 isogenic cell lines (Figure 4G) was independently repeated three times with similar results.</p> <p>Western blot analysis of Colo320 isogenic cell lines (Figure 4G) was independently repeated two times with similar results.</p> <p>5-FU sensitivity testing of isogenic cells lines (Figure 4I-J) was independently repeated three times with similar results.</p> <p>5-FU sensitivity testing of organoids (Figure 4K-L) was independently repeated three times with similar results.</p>
Randomization	<p>Experimental subgroups were either determined by KRAS codon-specific mutation status, a non-random procedure, or (in the RECOURSE trial) by treatment status (FTD/TPI vs placebo), a random procedure. In the real-world cohort-based analyses, we reported subgroup-specific differences in baseline characteristics in the main text and Table 1, and adjusted for these differences using multivariate Cox regression. In the RECOURSE trial-based analyses, we reported subgroup-specific differences in baseline characteristics in the main text and Table 2, and adjusted for these differences using multivariate Cox regression. Furthermore, we specifically compared the KRAS G12 mutant subgroup with the other RAS/RAF mutant subgroup, which were two subgroups with very similar baseline characteristics (see Table 1 and Table 2).</p>
Blinding	<p>Discovery cohort HMF</p> <p>Collection of genomics data and bioinformatics analysis were performed prospectively and hence blinded for clinical outcomes. Collection of clinical outcomes was performed by trained research nurses and medical doctors at the sites of inclusion, who were blinded, as they lacked knowledge about the research question of our study. Data analysis happened in an unblinded fashion.</p> <p>Real-world Cohort (UK and Italy)</p> <p>Collection of clinical outcomes was performed by trained research nurses and medical doctors at the sites of inclusion, who were blinded, as they lacked knowledge about the research question of our study. Data analysis happened in an unblinded fashion.</p> <p>RECOURSE trial</p> <p>The RECOURSE trial was a double-blind study. Details on this process can be found in the original publication (Mayer et al, NEJM 2015). In this re-analysis, data analysis was prespecified in a formal and detailed data request before access to the data was granted, but happened in an unblinded fashion.</p> <p>In vitro experimentation occurred in an unblinded fashion, as the experimenters generated the appropriate models for their experiments, but given standardized procedures for data readout (automated cell viability readouts and Western blotting) the risk of potential biases was limited.</p>

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials &amp; experimental systems

n/a	Involvement
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

## Methods

n/a	Involvement
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

## Antibodies used

The following primary antibodies were used: phospho-Histone H2A.X (Ser139) (#05-636) was purchased from Sigma-Aldrich; HSP 90 $\alpha$ / $\beta$  (#sc-13119) was purchased from Santa Cruz Biotechnology. The following secondary antibodies were used: Anti-mouse IgG, HRP-linked antibody (#7076, Cell Signaling Technology). All antibodies were diluted 1:1000 in PBS plus 5% BSA.

## Validation

phospho-Histone H2A.X (Ser139) (#05-636, Sigma-Aldrich): <https://www.sigmaaldrich.com/NL/en/product/mm/05636i>

HSP 90 $\alpha$ / $\beta$  (#sc-13119, Santa Cruz Biotechnology): <https://www.scbt.com/p/hsp-90alpha-beta-antibody-f-8>

Anti-mouse IgG, HRP-linked antibody (#7076, Cell Signaling Technology): <https://www.cellsignal.com/products/secondary-antibodies/anti-mouse-igg-hrp-linked-antibody/7076>

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

## Cell line source(s)

SW48 isogenic cell lines (KRAS wild type, KRAS G12V mutant): Provided by Alberto Bardelli (IFOM, Milan) and his team. Colo320 parental cell line (KRAS wild type): Provided by Rene Bernards and his team.

All organoid lines were established within our own research group using patient-derived tumor material.

## Authentication

SW48 isogenic cell lines: We confirmed KRAS WT/G12V status with targeted sequencing. Colo320 isogenic cell lines: We confirmed KRAS WT/G12D status with targeted sequencing. All organoid lines: we confirmed KRAS codon-specific mutation status with targeted sequencing and performed SNP testing on organoids and primary patient material to confirm the patient of origin.

## Mycoplasma contamination

All cell and organoid lines were confirmed to be negative for Mycoplasma contamination.

Commonly misidentified lines  
(See [ICLAC](#) register)

No commonly misidentified lines were used.

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

## Clinical trial registration

Discovery cohort HMF: NCT01855477  
RECOURSE study: NCT01607957  
Real-World Cohort (UK and Italy) retrospective analysis no clinical trial registration.

## Study protocol

Discovery cohort HMF: The study protocol of NCT01855477 has not been published publicly, but is available upon reasonable request.  
Real-World Cohort (UK and Italy) retrospective analysis. Study protocol available upon request.  
RECOURSE study: [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1414325/suppl\\_file/nejmoa1414325\\_protocol.pdf](https://www.nejm.org/doi/suppl/10.1056/NEJMoa1414325/suppl_file/nejmoa1414325_protocol.pdf)

## Data collection

Discovery cohort HMF  
Data was collected by trained clinicians and research nurses at 13 academic, teaching, and regional hospitals throughout the Netherlands. All patients were accrued between April 2016 and January 2018.

Real-world validation cohort  
Retrospective collection of clinical-pathological and molecular data was performed by trained clinicians and research nurses in 36 academic, teaching and regional hospitals in Italy and the UK (see Supplementary Table 7 for participating centers and inclusion numbers) for all consecutive mCRC patients treated with FTD/TPI was performed between November 2016 and March 2022.

RECOURSE study  
Patients were accrued at multiple hospitals globally, as described in the original publication (Mayer et al, NEJM, 2015). All patients were accrued between June 17, 2012, and October 8, 2013.

In the real-world discovery analysis, we searched for genome-wide somatic variants associated with OS and time on FTD/TPI treatment as endpoints. In the real-world validation analysis, the primary and secondary objective was to assess the association of KRAS G12 mutation with OS and PFS, respectively, in the population as a whole and in RAS/RAF mutation-based subpopulations. All endpoints used in real-life analyses were measured from start of FTD/TPI treatment and evaluated at participating institutions over the treatment course according to local practice. In our re-analysis of the RECURSE trial, we tested OS and PFS benefit of FTD/TPI vs placebo as primary and secondary endpoints, respectively, in subgroups defined by codon-specific KRAS mutation status. This was in accordance with the hierarchy of endpoints prespecified in the RECURSE trial protocol and these re-analyses were prespecified in a formal data request to the sponsor of the RECURSE study before access to the data was granted.